We are live on ! Find out more
IDYA icon

IDEAYA Biosciences

204 hedge funds and large institutions have $2.04B invested in IDEAYA Biosciences in 2025 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 78 increasing their positions, 74 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

32% more capital invested

Capital invested by funds: $1.54B → $2.04B (+$493M)

3.3% more ownership

Funds ownership: 107.24%110.54% (+3.3%)

5% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 74

0% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 31

1% less funds holding

Funds holding: 207204 (-3)

68% less call options, than puts

Call options by funds: $887K | Put options by funds: $2.77M

Holders
204
Holders Change
-3
Holders Change %
-1.45%
% of All Funds
2.69%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.05%
New
31
Increased
78
Reduced
74
Closed
31
Calls
$887K
Puts
$2.77M
Net Calls
-$1.89M
Net Calls Change
-$2.73M
Name Holding Trade Value Shares
Change
Change in
Stake
PNC Financial Services Group
151
PNC Financial Services Group
Pennsylvania
$70.3K +$18K +940 +39%
Nisa Investment Advisors
152
Nisa Investment Advisors
Missouri
$69.4K +$2.13K +111 +3%
PA
153
Parallel Advisors
California
$68.5K +$26.3K +1,369 +72%
Daiwa Securities Group
154
Daiwa Securities Group
Japan
$66K +$8.37K +436 +16%
Carson Wealth (CWM LLC)
155
Carson Wealth (CWM LLC)
Nebraska
$66K +$15K +782 +33%
AB
156
Amalgamated Bank
New York
$61K
MYIA
157
Mount Yale Investment Advisors
Colorado
$60.8K +$55.5K +2,893 New
KBC Group
158
KBC Group
Belgium
$56K -$29K -1,514 -36%
US Bancorp
159
US Bancorp
Minnesota
$49.3K +$9.98K +520 +28%
SCM
160
Sterling Capital Management
North Carolina
$47.5K +$41.7K +2,172 +2,413%
GFM
161
GF Fund Management
China
$46.5K
VCM
162
Versant Capital Management
Arizona
$43.3K +$28.7K +1,495 +264%
Comerica Bank
163
Comerica Bank
Texas
$32.8K +$1.57K +82 +6%
Russell Investments Group
164
Russell Investments Group
United Kingdom
$21.7K -$407K -21,209 -95%
GI
165
GAMMA Investing
California
$19.7K +$9.61K +501 +115%
FHA
166
First Horizon Advisors
Tennessee
$19.6K +$4.93K +257 +38%
AUB
167
Atlantic Union Bankshares
Virginia
$16.8K +$15.3K +800 New
Group One Trading
168
Group One Trading
Illinois
$15.2K -$31.6K -1,648 -70%
BNP Paribas Asset Management
169
BNP Paribas Asset Management
France
$15K +$13.4K +701 New
SC
170
SouthState Corp
Florida
$10.5K +$9.59K +500 New
PAS
171
Point72 Asia (Singapore)
Singapore
$10K +$9.13K +476 New
AF
172
Allworth Financial
California
$7.61K +$2.61K +136 +60%
HNB
173
Huntington National Bank
Ohio
$6.94K -$1.09K -57 -15%
MPWT
174
MassMutual Private Wealth & Trust
Connecticut
$6.12K +$1.69K +88 +43%
EWA
175
EverSource Wealth Advisors
Alabama
$6.01K +$5.07K +264 +1,200%

IDYA Hedge Fund Activity: Q2 2025 in Review

204 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in IDEAYA Biosciences (IDYA) for Q2 2025, worth a combined $2.04B — up 32% from $1.54B a quarter earlier.

Fund positioning in IDYA was balanced in Q2 2025: 31 funds opened new positions, 31 closed out, 78 added to existing stakes and 74 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $93.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $30.1M.

  • 204 institutional investors held IDEAYA Biosciences (IDYA) as of Q2 2025, down from 207 in Q1 2025.
  • Funds reported $2.04B of IDEAYA Biosciences stock for Q2 2025, up 32% quarter-over-quarter.
  • 31 funds opened new IDEAYA Biosciences positions in Q2 2025 and 31 closed out, a net change of 0 holders.
  • The largest IDEAYA Biosciences buyer in Q2 2025 was Point72 Asset Management, an estimated $93.8M added.
  • The largest IDEAYA Biosciences seller in Q2 2025 was T. Rowe Price Associates, an estimated $30.1M sold.

Based on aggregated 13F filings for Q2 2025.